Cargando…

Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer

Lung cancer is the most common cancer worldwide and the most common cause of cancer-related death. Non-small-cell lung cancer comprises ~87% of newly diagnosed cases of lung cancer, and nearly one-third of these patients have stage III disease. Despite improvements in the treatment of stage IV lung...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shafique, Michael R, Robinson, Lary A, Antonia, Scott
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937504/ https://www.ncbi.nlm.nih.gov/pubmed/29760563 http://dx.doi.org/10.2147/CMAR.S148009

Ejemplares similares

Durvalumab for urothelial carcinoma, non-small cell lung cancer
Publicado: (2019)

Predictors of lung injury during durvalumab maintenance therapy following concurrent chemoradiotherapy in unresectable locally advanced non‐small cell lung carcinoma
por: Hirama, Nobuyuki, et al.
Publicado: (2023)

Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context
por: Gullapalli, Sneha, et al.
Publicado: (2020)

Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer
por: Sankar, Kamya, et al.
Publicado: (2022)

Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer
por: Hassanzadeh, Comron, et al.
Publicado: (2020)

Molecular evidence of viral DNA in non-small cell lung cancer and non-neoplastic lung
por: Robinson, Lary A, et al.
Publicado: (2016)

Choice of Treatment for Stage IA Non-small Cell Lung Cancer Patients Ineligible for Surgery: Ablation or Stereotactic Body Radiotherapy?
por: Liang, Long, et al.
Publicado: (2020)

Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer
por: Preti, Beatrice T. B., et al.
Publicado: (2023)

Reply to: Comment on ‘Molecular evidence of viral DNA in non-small cell lung cancer and non-neoplastic lung’
por: Robinson, Lary A, et al.
Publicado: (2017)

Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer
por: Nishimura, Ari, et al.
Publicado: (2021)

Study protocol for JCOG1807C (DEEP OCEAN): a interventional prospective trial to evaluate the efficacy and safety of durvalumab before and after operation or durvalumab as maintenance therapy after chemoradiotherapy against superior sulcus non-small cell lung cancer
por: Aokage, Keiju, et al.
Publicado: (2022)

Durvalumab plus novel agents in non-small cell lung cancer—a new COAST on the horizon?
por: Dempke, Wolfram C. M., et al.
Publicado: (2022)

Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer
por: Pennock, Michael, et al.
Publicado: (2023)

Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer
por: Nakamura, Masakatsu, et al.
Publicado: (2020)

Asthma caused by durvalumab after chemoradiotherapy in two patients with non‐small cell lung cancer
por: Uemura, Takehiro, et al.
Publicado: (2021)

Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)
por: Rosenberg, Jonathan E., et al.
Publicado: (2023)

Maintenance Therapies for Non-Small Cell Lung Cancer
por: Blais, Normand, et al.
Publicado: (2014)

Rapidly Growing Locally Advanced Non-Small Cell Lung Cancer Treated with Definitive Chemoradiotherapy Using Adaptive Volumetric Modulated Arc Therapy Followed by Durvalumab Maintenance: A Case Report
por: Sakai, Keisuke, et al.
Publicado: (2022)

Myositis induced by durvalumab in a patient with non‐small cell lung cancer: A case report
por: Kobayashi, Miyuki, et al.
Publicado: (2020)

Use of durvalumab in stage III non‐small‐cell lung cancer based on eligibility for the PACIFIC study
por: Boys, Emma, et al.
Publicado: (2023)

Radiofrequency ablation of stage IA non–small cell lung cancer in patients ineligible for surgery: results of a prospective multicenter phase II trial
por: Palussière, J., et al.
Publicado: (2018)

Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)—a German radiation oncology survey
por: Käsmann, Lukas, et al.
Publicado: (2020)

Impact of viral presence in tumor on gene expression in non-small cell lung cancer
por: Kim, Youngchul, et al.
Publicado: (2018)

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
por: Spigel, David R., et al.
Publicado: (2022)

Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study)
por: Yamada, Tadaaki, et al.
Publicado: (2020)

The Ineligibility of Antipyrin in Pneumonia
Publicado: (1886)

Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience
por: Botticella, Angela, et al.
Publicado: (2019)

Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events
por: Miura, Yu, et al.
Publicado: (2020)

Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer
por: Landman, Yosef, et al.
Publicado: (2021)

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer
por: Alessi, Joao V, et al.
Publicado: (2023)

Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma
por: Cheng, Li, et al.
Publicado: (2021)

Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer
por: Wang, Lan, et al.
Publicado: (2021)

Durvalumab for Extensive-Stage of Small-Cell Lung Cancer With Lambert-Eaton Myasthenic Syndrome
por: Machiyama, Hirotomo, et al.
Publicado: (2023)

Case Report: Limbic encephalitis following treatment with durvalumab for small-cell lung cancer
por: Moss, Thomas T., et al.
Publicado: (2023)

Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial
por: Senan, S., et al.
Publicado: (2022)

Primary systemic therapy for patients with brain metastases from lung cancer ineligible for targeted agents
por: Nieder, Carsten, et al.
Publicado: (2022)

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study
por: Johnson, Melissa L., et al.
Publicado: (2023)

Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation
por: Choi, Yong Won, et al.
Publicado: (2015)

Percutaneous Radiofrequency Ablation of Thyroid Carcinomas Ineligible for Surgery, in the Elderly
por: Marcy, Pierre Yves, et al.
Publicado: (2023)

Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy
por: Jiang, Meilin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0l8onkv448idqaqhj6c96k9tp6